Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Mechanisms and optimization of in vivo delivery of lipophilic siRNAs.

Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, Manoharan M, Stoffel M.

Nat Biotechnol. 2007 Oct;25(10):1149-57. Epub 2007 Sep 16.

PMID:
17873866
2.

Silencing of mouse hepatic lanosterol 14-alpha demethylase down-regulated plasma low-density lipoprotein cholesterol levels by short-term treatment of siRNA.

Xu B, Wang C, Yang J, Mao G, Zhang C, Liu D, Tai P, Zhou B, Xia G, Zhang M.

Biol Pharm Bull. 2008 Jun;31(6):1182-91.

3.

Mechanistic insights into LDL nanoparticle-mediated siRNA delivery.

Jin H, Lovell JF, Chen J, Lin Q, Ding L, Ng KK, Pandey RK, Manoharan M, Zhang Z, Zheng G.

Bioconjug Chem. 2012 Jan 18;23(1):33-41. doi: 10.1021/bc200233n. Epub 2011 Dec 13.

PMID:
22142191
4.

RNAi-mediated gene silencing in non-human primates.

Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I.

Nature. 2006 May 4;441(7089):111-4. Epub 2006 Mar 26.

PMID:
16565705
5.

Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery.

Chen Q, Butler D, Querbes W, Pandey RK, Ge P, Maier MA, Zhang L, Rajeev KG, Nechev L, Kotelianski V, Manoharan M, Sah DW.

J Control Release. 2010 Jun 1;144(2):227-32. doi: 10.1016/j.jconrel.2010.02.011. Epub 2010 Feb 17.

PMID:
20170694
6.

Physiological importance of SR-BI in the in vivo metabolism of human HDL and LDL in male and female mice.

Brodeur MR, Luangrath V, Bourret G, Falstrault L, Brissette L.

J Lipid Res. 2005 Apr;46(4):687-96. Epub 2005 Jan 16.

7.

In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.

Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A.

Toxicol Appl Pharmacol. 2009 Apr 1;236(1):97-108. doi: 10.1016/j.taap.2009.01.014. Epub 2009 Jan 29.

PMID:
19371615
8.

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP.

Nature. 2004 Nov 11;432(7014):173-8.

9.

SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux.

Pagler TA, Rhode S, Neuhofer A, Laggner H, Strobl W, Hinterndorfer C, Volf I, Pavelka M, Eckhardt ER, van der Westhuyzen DR, Schütz GJ, Stangl H.

J Biol Chem. 2006 Apr 21;281(16):11193-204. Epub 2006 Feb 16.

10.

Gene silencing by systemic delivery of synthetic siRNAs in adult mice.

Sørensen DR, Leirdal M, Sioud M.

J Mol Biol. 2003 Apr 4;327(4):761-6.

PMID:
12654261
11.

The design and exogenous delivery of siRNA for post-transcriptional gene silencing.

Gilmore IR, Fox SP, Hollins AJ, Sohail M, Akhtar S.

J Drug Target. 2004 Jul;12(6):315-40. Review.

PMID:
15545082
12.

Efficient delivery of siRNA for inhibition of gene expression in postnatal mice.

Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H.

Nat Genet. 2002 Sep;32(1):107-8. Epub 2002 Jul 29.

PMID:
12145662
13.

Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells.

Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4975-7.

PMID:
15341962
14.

Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo.

Breunig M, Hozsa C, Lungwitz U, Watanabe K, Umeda I, Kato H, Goepferich A.

J Control Release. 2008 Aug 25;130(1):57-63. doi: 10.1016/j.jconrel.2008.05.016. Epub 2008 May 24.

PMID:
18599144
16.

Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery.

Golzio M, Mazzolini L, Moller P, Rols MP, Teissié J.

Gene Ther. 2005 Feb;12(3):246-51.

PMID:
15592423
17.

Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles.

Nakayama T, Butler JS, Sehgal A, Severgnini M, Racie T, Sharman J, Ding F, Morskaya SS, Brodsky J, Tchangov L, Kosovrasti V, Meys M, Nechev L, Wang G, Peng CG, Fang Y, Maier M, Rajeev KG, Li R, Hettinger J, Barros S, Clausen V, Zhang X, Wang Q, Hutabarat R, Dokholyan NV, Wolfrum C, Manoharan M, Kotelianski V, Stoffel M, Sah DW.

Mol Ther. 2012 Aug;20(8):1582-9. doi: 10.1038/mt.2012.33. Epub 2012 Jun 5.

18.

Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells.

Muratovska A, Eccles MR.

FEBS Lett. 2004 Jan 30;558(1-3):63-8. Erratum in: FEBS Lett. 2004 May 21;566(1-3):317.

19.

Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.

Liu B.

Brief Funct Genomic Proteomic. 2007 Jun;6(2):112-9. Epub 2007 Jul 31. Review.

PMID:
17670766
20.

Efficient reduction of serum cholesterol by combining a liver-targeted gene delivery system with chemically modified apolipoprotein B siRNA.

Kang JH, Tachibana Y, Obika S, Harada-Shiba M, Yamaoka T.

J Control Release. 2012 Oct 28;163(2):119-24. doi: 10.1016/j.jconrel.2012.08.030. Epub 2012 Sep 4.

PMID:
22974833

Supplemental Content

Support Center